Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Down 29.7% in December

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 73,076 shares, a drop of 29.7% from the December 15th total of 103,943 shares. Based on an average trading volume of 86,065 shares, the short-interest ratio is currently 0.8 days. Approximately 5.5% of the shares of the stock are short sold. Approximately 5.5% of the shares of the stock are short sold. Based on an average trading volume of 86,065 shares, the short-interest ratio is currently 0.8 days.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 3.05% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce”.

Galmed Pharmaceuticals Price Performance

GLMD traded down $0.01 on Friday, hitting $0.77. 80,028 shares of the company were exchanged, compared to its average volume of 75,579. The firm has a fifty day simple moving average of $0.93 and a two-hundred day simple moving average of $1.33. Galmed Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $3.50.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.